Global Market for Therapies for Rheumatoid Arthritis - Expected to Increase at a CAGR of 1.3% by 2020 - Research and Markets

News provided by

Research and Markets

02 Aug, 2016, 20:10 BST

DUBLIN, August 2, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Therapies for Rheumatoid Arthritis: Technologies and Global Markets" report to their offering.

The global market for therapies for rheumatoid arthritis reached $19.0 billion in 2014. The market is expected to reach nearly $21.3 billion by 2020 from $19.9 billion in 2015, increasing at a compound annual growth rate (CAGR) of 1.3% from 2015 to 2020.

This report provides an overview of the global markets, therapies, and related technologies for treating Rheumatoid Arthritis (RA).

This includes analysis of U.S. as well as international market trends, with data from 2014, 2015, and projections of compound annual growth rates (CAGRs) through 2020.

There is a discussion covering suppliers of therapeutic products for RA and analysis based on market share, product types, and geography (where data is available), as well as an overview of the disease including etiology, epidemiology, pathophysiology, risk factors and co-morbidities, and progression and outcomes.

An in-depth pipeline analysis, and biologic agents, both anti -TNF and non-TNF related currently under investigation or newly approved for use by the FDA are highlighted.

Companies Mentioned:

  • AB Science
  • Abbott Laboratories
  • Amgen Inc.
  • Astellas
  • Baxalta Inc.
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Celgene Corp.
  • Celltrion Inc.
  • Coherus Biosciences Inc.
  • Daiichi Sankyo Co. Ltd.
  • Eisai
  • ELI Lilly
  • Fujifilm Kyowa Kirin Biologics Co. Ltd.
  • Glaxosmithkline
  • Incyte Corp.
  • Johnson & Johnson
  • Kineta Inc.
  • Mabtech AB
  • Mycenax Biotech Inc.
  • Novartis AG
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer
  • Roche
  • Samsung Biologics Co. Ltd.
  • Takeda Pharmaceuticals
  • UCB Group/Immunomedics

Key Topics Covered:

1: Introduction

2: Summary

3: Disease Overview

4: Disease Management

5: Unmet Need And Opportunity

6: Pipeline Assessment

7: Patent Assessments

8: Company Profiles

9: Drivers And Barriers

For more information visit http://www.researchandmarkets.com/research/3l2mz8/therapies_for

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets